

Table I. Gram-Negative Bacilli [1] Norton Outpatient Practices 2023	Number Tested	Penicillins		Cephalosporins			Monobactam	Carbapenems		Aminoglycosides			Others									
		Ampicillin	Amoxicillin/Clavulanate	Ampicillin/Sulbactam	Piperacillin/Tazobactam (%S) [2]	Piperacillin/Tazobactam (%SDD) [2]	Oral cephalosporins for uncomplicated UTI		Ertapenem	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin	Levofloxacin	Nitrofurantoin [4]	Trimeth/Sulfa					
							Cefazolin	Cefepime (%S) [3]	Cefepime (%SDD) [3]	Ceftazidime	Ceftriaxone	Aztreonam										
Acinetobacter baumannii complex [5]	15	R	R	93		R	93	93		R		R	100	*	93	93	87	100	87			
Other Acinetobacter species	15	R	R	80			93	80					93	91	87	87	93	100	87			
Aeromonas species	12		0	8			17	92	100	67	*		83	*	100		92	100	100			
Citrobacter freundii complex [6]	151	R	R	R	*	*	R	99	0	88	84	*	99	100	*	97	96	89	93	95	88	
Citrobacter koseri	232	R	99	98	*	*	98	99	1	99	99	*	100	100	*	98	99	97	97	86	96	
Enterobacter cloacae complex [7]	206	R	R	R	63	11	R	88	6	73	64	58	93	100	100	95	97	94	95	27	91	
Escherichia coli	10928	55	89	63	98	1	92	76	95	1	96	94	95	99	99	99	92	94	80	84	98	77
Hafnia alvei	13	R	R	R	*	*	R	100	0	69	62	*	92	100	*	100	100	92	92	*	100	
Klebsiella aerogenes	202	R	R	R	75	0	R	98	1	85	81	75	99	100	100	99	99	98	98	32	97	
Klebsiella oxytoca	199	R	90	67	*	*	34	94	1	94	91	*	100	100	*	93	93	87	92	83	87	
Klebsiella ozaenae	11	0	91	55	*	*	55	91	0	91	82	*	100	100	*	91	91	64	64	36	73	
Klebsiella pneumoniae	1491	R	96	87	96	2	96	88	96	1	97	96	96	100	100	98	97	92	96	56	91	
Kluyera ascorbata	19	16	58	42	*	*	37	89	0	74	74	*	95	100	*	84	89	47	47	82	68	
Morganella morganii	72	R	R	3	*	*	R	97	1	76	88	*	100	100	*	86	90	81	82	R	78	
Pantoea agglomerans group	13	8	100	100	*	*	15	100	0	100	92	*	100	100	*	100	100	100	100	*	100	
Proteus mirabilis	702	86	98	93	100	0	96	80	98	1	99	97	91	99	100	99	96	96	93	94	R	85
Proteus vulgaris	28	R	93	68	*	*	R	93	0	89	14	*	100	100	*	96	96	89	89	R	89	
Providencia rettgeri	18	R	R	56	*	*	R	89	11	33	100	*	100	100	*	100	94	94	89	R	94	
Pseudomonas aeruginosa	313	R	R	R	97		R	97	97	R		84	R	97	94	97	97	87	83	R	R	
Pseudomonas putida/fluorescens	14				*		93	100				*	93	*	100	93	93	93				
Raoultella ornithinolytica	22	R	91	73	*	*	86	95	5	95	100	*	100	100	*	95	100	82	86	77	68	
Salmonella species	19	84	95	84	*	*	R	100	0	95	95	*			R	R	R	82			95	
Serratia marcescens	66	R	R	R	83	9	R	100	0	67	74	70	100	100	96	97	88	92	95	R	97	
Stenotrophomonas maltophilia	26	R	R	R	R	R	R			27	R	R	R	R	R	R	R	100			96	

For antimicrobials listed, number shown is the percentage of unique isolates susceptible by current CLSI breakpoints, unless otherwise noted.

Please exercise discretion when data are reviewed for species with fewer than 30 isolates due to reduced statistical validity.

*Data is not shown for species or species/antimicrobial combinations that have fewer than 10 isolates.

A value of R indicates that this organism is intrinsically resistant to the antimicrobial agent.

[1] All organisms in this table are intrinsically resistant to oxacillin, penicillin, clindamycin, erythromycin, vancomycin, linezolid, and daptomycin.

[2] Interpretation of Susceptible (S) is based on dosage regimen of 3.375-4.5g administered every 6 hours as a 30 minute infusion. Interpretation of Susceptible Dose-Dependent (SDD) is based on a dosage regimen of 4.5g administered every 6 hours as a 3 hour infusion or 4.5g administered every 8 hours as a 4 hour infusion.

[3] Interpretation of Susceptible (S) is based on dosage regimen of 1g administered every 12 hours. Interpretation of Susceptible Dose-Dependent (SDD) is based on 2g administered every 8 hours.

[4] Nitrofurantoin susceptibility is based on urine isolates only.

[5] A. baumannii complex consists of the species A. baumannii, A. calcoaceticus, A. nosocomialis, and A. pittii.

[6] C. freundii complex consists of the species C. braakii, C. freundii, C. murliniae, C. sedlaki, C. werkmanii, and C. youngae.

[7] E. cloacae complex consists of the species E. asburiae, E. cloacae, E. hormaechei, E. kobei, E. ludwigii, and E. nimipressuralis.

Table II. Gram-Positive Cocci [1] Norton Outpatient Practices 2023	Number Tested	Penicillins				Cephalosporins		Gram + Coverage					Others				
		Amoxicillin/Clavulanate	Ampicillin	Oxacillin	Penicillin	Cefazolin	Ceftriaxone	Gentamicin Synergy	Clindamycin [2,3]	Erythromycin [3]	Vancomycin	Linezolid	Daptomycin [4]	Levofloxacin	Nitrofurantoin [3]	Tetracycline	Trimeth/Sulfa
Staphylococcus aureus	1620	64		64		64			79	45	99	100	99			91	99
Methicillin-resistant S. aureus	583	0		0		0			76	18	100	100	99			92	98
Methicillin-susceptible S. aureus	1037	100		100		100			81	61	99	100	99			91	99
Staphylococcus capitis	10	100		100		100			*	*	100	100	100		*	70	100
Staphylococcus epidermidis	650	50		50		50			56	32	100	99	99		99	78	70
Staphylococcus haemolyticus	102	31		31		31			*	*	100	100	100		100	69	84
Staphylococcus hominis	48	54		54		54			*	*	100	100	100		100	69	73
Staphylococcus lugdunensis	176	89		89		89			87	85	100	100	100		100	95	97
Staphylococcus simulans	55	80		80		80			*	*	100	100	100		98	91	98
Other coagulase-negative staphylococci	59	51		51		51			57	81	100	100	97		95	83	95
Enterococcus faecalis	184		99		99	R	R	86	R	24	99	100	100		99	26	R
Other Enterococcus species	18		72		72	R	R	78	R	*	72	100	100		*	33	R
Group A Streptococcus (S. pyogenes)	13		100		100		100		91	91	100			100		77	R
Group B Streptococcus (S. agalactiae)	435		100		100		100		34	25	100			99		13	R
Streptococcus anginosus [5]	49		98		98		100		76	46	100			96		29	
Streptococcus constellatus [5]	24		92		100		100		79	63	100			100		54	
Streptococcus intermedius [5]	15		100		100		100		67	33	100			100		33	
Streptococcus pneumoniae	38	97			See Table III		See Table III		86	38	100			100		76	76
Viridans streptococci	38		92		84		95		64	21	100			95		68	
Aerococcus urinae	186		94		94		96		*	*	100			69		81	R
Aerococcus viridans	34		94		91		88		*	*	100			62		85	85

For antimicrobials listed, number shown is the percentage of unique isolates susceptible by current CLSI breakpoints, unless otherwise noted.

Please exercise discretion when data are reviewed for species with fewer than 30 isolates due to reduced statistical validity.

*Data is not shown for species or species/antimicrobial combinations that have fewer than 10 isolates.

A value of R indicates that this organism is intrinsically resistant to the antimicrobial agent.

[1] All organisms in this table are intrinsically resistant to aztreonam. All Enterococcus species are intrinsically resistant to cephalosporins, clindamycin, trimethoprim/sulfamethoxazole, and aminoglycosides (except for synergy).

[2] MRSA: 13% inducible resistance, 10% constitutive resistance; MSSA: 16% inducible resistance, 2% constitutive resistance; Coag-neg Staph (all species): 3% inducible resistance, 17% constitutive resistance.

[3] Clindamycin and erythromycin data are based on non-urine isolates only. Nitrofurantoin susceptibility is based on urine isolates only.

[4] For E. faecium only, daptomycin interpretation of SDD is based on dosage regimen of 8-12 mg/kg administered every 24 hours and is intended for serious E. faecium infections only. There is no S category for E. faecium with daptomycin. For other Enterococcus species, daptomycin interpretation of S is based on a dosage regimen of 6 mg/kg administered every 24 hours.

[5] S. anginosus, S. constellatus, and S. intermedius together comprise the S. anginosus complex.

Table III.
Streptococcus
pneumoniae
Penicillin & Ceftriaxone

Norton Outpatient
Practices 2023

	Penicillin - IV meningitis	Penicillin - IV non-meningitis	Penicillin - Oral	Ceftriaxone - IV meningitis	Ceftriaxone - IV non-meningitis
Percent Susceptible	66	97	66	87	100
Percent Intermediate	-	3	16	13	0
Percent Resistant	34	0	18	0	0